Abstract: Disclosed are a composition comprising a compound as shown in formula (I) and a preparation method therefor, and the use of same in the preparation of a drug for treating ophthalmic diseases.

Abstract: Provided is an aldehyde binder, specifically, disclosed is a compound as represented by formula (II) or a pharmaceutically acceptable salt.

Abstract: Embodiments of the present invention relate to a call record synchronization method, a cloud platform, and a terminal. The method includes: detecting, by a first terminal, an input operation for requesting to display a call record; and after the first terminal detects the input operation, displaying, by the first terminal, a merged call record, where the merged call record is a call record obtained after merging of a call record of the first terminal and a call record of a second terminal, and the merged call record includes a device identifier of the first terminal and/or a device identifier of the second terminal. According to the embodiments of the present invention, a user can use the merged call record to identify call answering or making statuses on a plurality of terminals, without querying a plurality of call records. This improves user experience.

Abstract: Disclosed are a solid form, a crystalline form, and crystal form A of a compound of formula (I) used as an FXR agonist, and a preparation method therefor. Also comprised is an application of the compound of formula (I) in preparation of a medication for treating nonalcoholic steatohepatitis (NASH).

Abstract: Provided in the present invention is a T cell receptor (TCR) having the property of binding to a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 2 times the binding affinity of the wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Also provided in the present invention is a fusion molecule of such TCRs with therapeutic agents. Such TCRs can be used alone or in combination with therapeutic agents, so as to target tumor cells presenting the FMNKFIYEI-HLA A0201 complex.

Abstract: Disclosed are a process route of a compound of a compound of formula (IV), a crystal form and a preparation method therefor. Also disclosed is an application of the crystal form in preparation of drugs for treating diseases associated with SSAO.

Abstract: An anode active material comprises a silicon-carbon secondary particle comprising a composite having an exterior conformal carbon coating and formed of type I primary particles. Each type I primary particle comprises a core particle of interconnected silicon, the interconnected silicon formed of nano-sized silicon particles each connected to at least one other particle, inner pores internal to the core particle and defined by the interconnected silicon, an internal carbon coating on internal wall surfaces of the inner pores and a conformal carbon coating on the core particle.

Abstract: A profile download method includes a primary device obtaining an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID. The primary device receives the profile download information from the mobile operator server and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and where the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

Abstract: A call record synchronization method includes detecting, by a first terminal, an input operation for requesting to display a call record. The method further includes, after the first terminal detects the input operation, displaying, by the first terminal, a merged call record, where the merged call record is a call record obtained after merging of a call record of the first terminal and a call record of a second terminal. The merged call record includes a device identifier of the first terminal and/or a device identifier of the second terminal.

Abstract: Localized superconcentrated electrolytes (LSEs) for use in systems with silicon-based or carbon/silicon composite-based anodes are disclosed. The LSEs include an active salt, a nonaqueous solvent in which the active salt is soluble, and a diluent in which the active salt has a solubility at least 10 times less than solubility of the active salt in the nonaqueous solvent. Systems including the LSEs also are disclosed.

Abstract: Methods, compositions and kits for quantitatively determining specified amounts of 11dhTxB2 in microliter to milliliter quantities of a given sample, wherein, the sample is a biological fluid. Specifically, the biological fluid is a quantity of 1 ml or less of urine from a human subject. The methods may be in the form of consolidated assays that can be run in a high throughput, automation format, such as an enzyme-linked immunosorbent assay (ELISA). Further, the ELISA may be modified into a chemiluminescence assay in order to increase sensitivity and linear range and to reduce the reaction time.

Abstract: The present invention relates to a crystal form of a compound of formula (I) and an application thereof in preparing a drug for treating an ophthalmic disease.

Abstract: This application relates to the field of communications technologies, and in particular, to a profile download technology. In a profile download method, a primary device obtains an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID; receives the profile download information from the mobile operator server; and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Abstract: Electrolytes for lithium ion batteries with carbon-based, silicon-based, or carbon- and silicon-based anodes include a lithium salt; a nonaqueous solvent comprising at least one of the following components: (i) an ester, (ii) a sulfur-containing solvent, (iii) a phosphorus-containing solvent, (iv) an ether, (v) a nitrile, or any combination thereof, wherein the lithium salt is soluble in the solvent; a diluent comprising a fluoroalkyl ether, a fluorinated orthoformate, a fluorinated carbonate, a fluorinated borate, or a combination thereof, wherein the lithium salt has a solubility in the diluent at least 10 times less than a solubility of the lithium salt in the solvent; and an additive having a different composition than the lithium salt, a different composition than the solvent, and a different composition than the diluent.

Abstract: Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, and the use of same in the preparation of a drug for treating or preventing various conditions associated with FXR.

Abstract: The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for preparing a compound of formula I, comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, obtaining a compound of formula 11 from a reaction of the compound of formula 10, and obtaining the compound of formula I from a reaction of the compound of formula 11, as well as the intermediates used, the methods for preparing the intermediates and the use of the intermediates. The reaction conditions of the preparation method are mild, and some of the steps can convert multiple groups simultaneously, thereby effectively shortening the sequence of steps. The preparation method is suitable for industrialized production.

Abstract: The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: Provided are cell culture apparatus and method. The cell culture apparatus comprises a culture column and a perfusion system, the culture column comprising a first and a second tube-connecting caps and a support for cells to attach and grow thereon. The first and the second tube-connecting caps are respectively provided with a perfusion inlet and a perfusion outlet; The perfusion system comprises a culture medium storage device, a perfusion tube and a perfusion pump. A complete and closed culture column is formed in the cell culture device after the cells are inoculated, and the culturing is completed by the perfusion system to avoid contamination.